Indian pharma margins face pressure from costs and weak US demand, says Ind-Ra

The Indian pharmaceutical sector faces potential margin compression despite a strong start to FY27, according to an India Ratings report. Elevated input costs, logistical challenges, and weak demand in the U.S. generics market are cited as key headwinds, even as domestic sales grew 11.5% year-on-year in the first quarter.